Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Accumulated Depreciation (2016 - 2024)

Historic Accumulated Depreciation for Fate Therapeutics (FATE) over the last 10 years, with Q4 2024 value amounting to $35.1 million.

  • Fate Therapeutics' Accumulated Depreciation fell 2622.52% to $35.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $35.1 million, marking a year-over-year decrease of 2622.52%. This contributed to the annual value of $35.1 million for FY2024, which is 2622.52% down from last year.
  • Latest data reveals that Fate Therapeutics reported Accumulated Depreciation of $35.1 million as of Q4 2024, which was down 2622.52% from $47.6 million recorded in Q4 2023.
  • Over the past 5 years, Fate Therapeutics' Accumulated Depreciation peaked at $47.6 million during Q4 2023, and registered a low of $11.1 million during Q4 2020.
  • Moreover, its 5-year median value for Accumulated Depreciation was $30.4 million (2022), whereas its average is $28.2 million.
  • As far as peak fluctuations go, Fate Therapeutics' Accumulated Depreciation soared by 7930.95% in 2022, and later crashed by 2622.52% in 2024.
  • Over the past 5 years, Fate Therapeutics' Accumulated Depreciation (Quarter) stood at $11.1 million in 2020, then skyrocketed by 52.73% to $16.9 million in 2021, then skyrocketed by 79.31% to $30.4 million in 2022, then skyrocketed by 56.75% to $47.6 million in 2023, then dropped by 26.23% to $35.1 million in 2024.
  • Its Accumulated Depreciation was $35.1 million in Q4 2024, compared to $47.6 million in Q4 2023 and $30.4 million in Q4 2022.